Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1778)	2/19/1999 2:29:00 PM
From: BMcV	Respond to of 10280

up 18, down 16 -- I would have preferred +2, but at least we're on the radar screens. First CNBC, then this morning in the car a little blurb on AM radio (WEEI, for the Bostonians out there). Looks like Gruntal downgraded SEPR while raising the price target to 155. They downgraded a while back, so they must have upgraded in between sometime I missed. Saw the CNBC on tape and was impressed with David Southwell. He backed off the "endorsement" of analysts's estimates a bit, stressing he only agreed with the assumptions they made to reach those estimates. Interestingly, he tried to portray the SEPR drugs as "new", in the sense that they can have very different properties from the parent drugs. Mark Haynes helped out, saying, "so these aren't just the old molecules with a new paint job, right?" Maybe after leveraging the name recognition of Prozac and Claritin, they are now trying to separate themselves in people's minds from all the drug delivery companies, which are a dime a dozen, and have been favorite analogies for industry analysts trying to characterize SEPR's business. here's the downgrade: biz.yahoo.com Friday February 19, 10:37 am Eastern Time Note: this article has a followup with more information. Gruntal Says Cuts Sepracor to Buy From Strong Buy, Ups Target to $155